|
Pinana JL, Heras I, Aiello TF, Garcia-Cadenas I, Vazquez L, Lopez-Jimenez J, Chorao P, Aroca C, Garcia-Vidal C, Arroyo I, Soler-Espejo E, Lopez-Corral L, Avendano-Pita A, Arrufat A, Garcia-Gutierrez V, Arellano E, Hernandez-Medina L, Gonzalez-Santillana C, Morell J, Hernandez-Rivas JA, Rodriguez-Galvez P, Mico-Cerda M, Guerreiro M, Campos D, Navarro D, Cedillo A, Martino R, Solano C; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses. 2023 Oct 8;15(10):2066. doi: 10.3390/v15102066. PubMed PMID: 37896843; PubMed Central PMCID: PMC10612015.
AÑO: 2023; IF: 3.8
|
37896843
|
Fonseca-Santos M, Bailen R, Lopez-Godino O, Herruzo-Delgado B, Bermudez MA, Garcia-Cadenas I, Huguet-Mas M, Ferra-Coll C, Esquirol A, Cortes-Rodriguez M, Yanez-Sansegundo L, Pascual-Cascon MJ, Heras I, Kwon M, Lopez-Corral L; Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular. Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide: A Study on Behalf of GETH-TC. Transplantation. 2024 Oct 1;108(10):2134-2143. doi: 10.1097/TP.0000000000005034. Epub 2024 Sep 24. PubMed PMID: 38685204.
AÑO: 2024; IF: 5.0
|
|
Pinana JL, Vazquez L, Heras I, Aiello TF, Lopez-Corral L, Arroyo I, Soler-Espejo E, Garcia-Cadenas I, Garcia-Gutierrez V, Aroca C, Chorao P, Olave MT, Lopez-Jimenez J, Gomez MA, Arellano E, Cuesta-Casas M, Avendano-Pita A, Gonzalez-Santillana C, Hernandez-Rivas JA, Roldan-Perez A, Mico-Cerda M, Guerreiro M, Morell J, Rodriguez-Galvez P, Labrador J, Campos D, Cedillo A, Vidal CG, Martino R, Solano C. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy. Front Oncol. 2024 Jun 19;14:1389345. doi: 10.3389/fonc.2024.1389345. eCollection 2024. PubMed PMID: 39015498; PubMed Central PMCID: PMC11250586.
AÑO: 2024; IF: 3.3
|
|
Kwon M, Gomez-Centurion I, Oarbeascoa G, Torres M, Martinez AP, Suarez-Lledo M, Chinea A, Cascon MJP, Vazquez L, Espigado I, Izquierdo I, Parody R, Cadenas IG, Calbacho M, Sierra PG, Heras I, Yanez L, Torrent A, Bautista G, Gonzalez S, Roldan E, Vallejo JC, Bailen R, Borrero A, Lopez-Jimenez J, Casas MAC, Solano C; Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC). Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain. Transplant Cell Ther. 2024 Oct;30(10):1033.e1-1033.e8. doi: 10.1016/j.jtct.2024.06.009. Epub 2024 Jun 12. PubMed PMID: 38871055.
AÑO: 2024; IF: 4.4
|
|
Mora E, Montoro J, Balaguer A, Rovira M, Cabrero M, Heras I, Ribera JM, Antelo G, Martin AA, Lopez Godino O, Torrent A, Villalba M, Chorao P, Sanz MA, Sanz J; Grupo Espanol de Trasplante Hematopoyetico (GETH). Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia. Bone Marrow Transplant. 2024 Aug;59(8):1137-1145. doi: 10.1038/s41409-024-02298-z. Epub 2024 May 16. PubMed PMID: 38755458.
AÑO: 2024; IF: 5.2
|